Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00525330 · ClinicalTrials.gov registry record · Phase 2
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone
A Phase 2 study of Type 2 Diabetes, sponsored by ActivX Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 213
- Enrollment target
- 1
- Study location
NCT00525330: Completed Phase 2 study of Type 2 Diabetes, sponsored by ActivX Biosciences.
NCT00525330 is a Phase 2 study of Type 2 Diabetes that has completed, run by ActivX Biosciences. The registered enrollment target is 213 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00525330, a Phase 2 study of Type 2 Diabetes, has completed, sponsored by ActivX Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 213 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the safety and efficacy of chronic therapy with KRP-104, a novel DPP-IV inhibitor, in patients with Type 2 Diabetes on stable metformin therapy. In addition, an estimate of how much of the HbA1c response is attributable to nocturnal coverage will be explored.
Conditions Studied
Interventions
- DRUG KRP-104 QD Drug: Placebo Drug: Metformin
- DRUG Placebo Drug: Metformin
- DRUG KRP-104 BID Drug: Placebo Drug: Metformin
Study Locations (1)
California
- - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2007-09 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00525330
The ClinicalTrials.gov registry entry for NCT00525330 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 213 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (81% lower). The listed sponsor is ActivX Biosciences, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 3 interventions - of which KRP-104 QD Drug: Placebo Drug: Metformin is the first listed.
NCT00525330 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00525330 about?
NCT00525330 is a clinical study titled "A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone". To assess the safety and efficacy of chronic therapy with KRP-104, a novel DPP-IV inhibitor, in patients with Type 2 Diabetes on stable metformin therapy. In addition, an estimate of how much of the HbA1c response is attributable to nocturnal coverage will be explored.
What is the current status of trial NCT00525330?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 213 participants. The study started on 2007-09. Estimated completion is 2008-08.
What conditions does trial NCT00525330 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT00525330?
The interventions under investigation include: KRP-104 QD Drug: Placebo Drug: Metformin (DRUG), Placebo Drug: Metformin (DRUG), KRP-104 BID Drug: Placebo Drug: Metformin (DRUG).
Who is sponsoring clinical trial NCT00525330?
This trial is sponsored by ActivX Biosciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00525330 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Renal Mechanism of SGLT2 Inhibition
RECRUITING · Phase 2
-
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
RECRUITING · Phase 2
-
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
RECRUITING · Phase 2
-
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
RECRUITING · Phase 2
-
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
ACTIVE NOT RECRUITING · Phase 2
-
Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
ACTIVE NOT RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.